Drug Trial Radar · NCT07541430
A Study in Adults With Desmoid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Apr 24, 2026
Primary completion
Jan 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Elpiscience (Suzhou) Biopharma, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, single-arm phase 2 clinical study designed to evaluate the efficacy, safety, tolerability, patient-reported outcomes (PROs), pharmacokinetics (PK), anti-drug antibody (ADA) and pharmacodynamics (PD) of ES014 in adult desmoid tumor patients.
Conditions
- Desmoid Tumor
Interventions
ES014Drug
ES014 is administered via intravenous infusion, 700mg once every 14 days.
ES014Drug
ES014 is administered via intravenous infusion, 1400mg once every 14 days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR) by IRC according to RECIST 1.1Time frame: 1-3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.